AP NEWS
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

BioSig’s Manuscript Accepted to IEEE Engineering in Medicine and Biology Conference 2019

May 2, 2019

Santa Monica, CA, May 02, 2019 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address unmet needs for the electrophysiology (EP) marketplace, today announced that the manuscript entitled “Evaluation of Real Time Catheter Tissue Contact using Unipolar Intracardiac Signal Morphology” has been accepted to the 41st International Engineering in Medicine and Biology Conference (EMBC), to be held in Berlin, Germany from July 23 – 27, 2019.

BioSig’s latest manuscript is discussing one of the most challenging objectives during EP studies – to achieve and maintain optimal contact between the catheter tip and myocardial tissue. The studies conducted by BioSig evaluated the morphology of unipolar intracardiac signals as an additional real time marker for contact evaluation and concluded that there was a correlation between the PR (for atria) and ST (for ventricles) segments and catheter contact force applied to the myocardium.

“We are very honored that our latest manuscript has again been recognized by the global biomedical and scientific community. We are fully committed to contributing our knowledge to develop better treatments for complex heart rhythm disturbances, and look forward to new findings, as we advance our R&D and clinical activities with the leading centers in the country,” commented Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc.

About EMBC 2019 The overarching theme for EMBC 2019 is “Biomedical engineering ranging from wellness to intensive care”. Consistent with this theme, the event will feature plenary keynotes from leading academic and industrial scientists, who will present aspects of innovation and translational engineering in biomedicine. The scientific tracks will cover the standard topics of the EMBS technical committees. Beside the scientific sessions, the congress exhibition will show biomedical companies, start-ups, biomedical institutes, universities, and provide networking opportunities for engineers, clinicians, other scientists, entrepreneurs and students. Cutting-edge research and innovation in biomedical engineering, healthcare technology and medical informatics will all be covered in this large conference. About IEEE The Institute of Electrical and Electronics Engineers (IEEE) is world’s largest association of technical professionals with more than 420,000 members in over 160 countries around the world. Its objectives are the educational and technical advancement of electrical and electronic engineering, telecommunications, computer engineering and allied disciplines.

About BioSig Technologies BioSig Technologies is a medical technology company developing a proprietary biomedical signal processing platform designed to improve the electrophysiology (EP) marketplace ( www.biosig.com ). Led by a proven management team and a veteran, independent Board of Directors, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The technology has been developed to address an unmet need in a large and growing market.

The Company’s first product, PURE EP™ System, is a novel cardiac signal acquisition and display system which is engineered to assist electrophysiologists in clinical decision-making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig’s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. BioSig has partnered with Minnetronix on technology development and received FDA 510(k) clearance for the PURE EP™ System in August 2018.

Forward-looking Statements This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Natasha Drapeau BioSig Technologies, Inc. Executive Vice President 12424 Wilshire Blvd, Ste 745 Los Angeles, CA 90025 ndrapeau@biosigtech.com 310-620-9320